Skip to main content
. 2022 Jan 10;322(3):E199–E210. doi: 10.1152/ajpendo.00320.2021

Figure 5.

Figure 5.

Inhibiting surface PAC1R trafficking attenuates PACAP-induced decrease in food intake and exaggerates PACAP-induced decrease in body weight. A and B: Western blot analysis showing PACAP promotes PAC1R trafficking from the membrane to the cytosol, which can be blocked by Dyngo-4a/Pitstop 2 and measured at 30 mins following PACAP injection. C: Dyngo-4a/Pitstop 2, dynamin and clathrin-dependent endocytosis inhibitors, briefly attenuate PACAP-induced suppression of food intake for 5 h postinjection. D: Dyngo-4a/Pitstop 2 does not prevent PACAP-induced reduction in body weight at 24 h. Data are expressed as means ± SE, *P < 0.05 (PACAP vs. control), #P < 0.05 (PACAP vs. PACAP+Dyngo-4a/Pitstop 2); n = 8 rats/group. PACAP, pituitary adenylate cyclase-activating polypeptide; PAC1R, pituitary adenylate cyclase receptor.